Skip to main
IBIO

iBio (IBIO) Stock Forecast & Price Target

iBio (IBIO) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

iBio is a clinical-stage biotechnology company that is leveraging AI and ML for the development of precision antibodies to treat obesity, cardiometabolic, and cardiopulmonary diseases. With multiple early clinical readouts expected in the next 12-18 months and an intriguing pipeline of novel antibodies, the Company's stock has a positive outlook, supported by its recent preclinical data for IBIO-610 and regulatory approval for IBIO-600. However, there are risks associated with investing in a clinical-stage company, including significant competition and the potential for IP infringement suits.

Bears say

iBio is a clinical-stage biotechnology company that is heavily relying on AI and ML for the development of precision antibodies to treat obesity and other diseases. However, the Company has a number of fundamental weaknesses, including a lack of current revenue-generating products, a history of cash burn, and the need to raise additional capital in the future. These factors, coupled with the risks associated with clinical trials and patent protection, make us hesitant to recommend a positive outlook for the stock.

iBio (IBIO) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of iBio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About iBio (IBIO) Forecast

Analysts have given iBio (IBIO) a Buy based on their latest research and market trends.

According to 5 analysts, iBio (IBIO) has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

iBio (IBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.